<DOC>
	<DOCNO>NCT01801293</DOCNO>
	<brief_summary>This single center , open-label , Phase 1 study determine mass balance GS-5806 follow administration single , oral dose radiolabeled [ 14C ] -GS-5806 healthy subject .</brief_summary>
	<brief_title>A Phase 1 Study Evaluate Pharmacokinetics , Metabolism , Excretion GS-5806</brief_title>
	<detailed_description />
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>Have calculate body mass index ( BMI ) 19 30 kg/m2 study screen . In opinion Investigator , subject must good health base upon medical history , physical examination ( include vital sign ) , screen baseline laboratory evaluation ( hematology , chemistry , urinalysis must fall within normal range local laboratory 's reference range unless result determine Investigator clinical significance ) . Agree utilize highly effective method contraception heterosexual intercourse baseline throughout study period 90 day follow discontinuation study drug . Refrain sperm donation Day 1 completion study continue least 90 day date last dose study drug . Have creatinine clearance ( CLcr ) &gt; 80 mL/min ( use CockcroftGault method ) base serum creatinine actual body weight measure screen evaluation . Anticipated , regular , average bowel movement 12 per day . Smokers , use nicotine nicotinecontaining product within 90 day prior first dose study drug . Smokers define subject report tobacco use and/or urine cotinine â‰¥200 ng/mL screening . A positive HIV1 antibody , Hepatitis B surface antigen ( HBsAg ) , Hepatitis C antibody test result . Have serious active medical psychiatric illness , opinion Investigator , would interfere subject treatment , assessment , compliance protocol . Have previously participate investigational trial involve administration investigational compound within 30 day prior study dose . Have participate study use radiomaterials ionize radiation otherwise expose significant diagnostic ( exclude dental Xrays ) , therapeutic , occupational radiation . Current alcohol substance abuse judge Investigator determine positive alcohol drug test screen baseline visit . Have poor venous access unable donate blood . Have donate blood within 56 day study dose plasma within 7 day study dose . Have vaccinate within 90 day study dosing , influenza vaccine , within 14 day prior study dose . Have take prescription medication overthecounter medication , include herbal product , medication affect gastric pH ( ie , antacid , H2RAs , and/or proton pump inhibitor ) within 28 day commence study drug dose exception vitamin , acetaminophen , ibuprofen . Have take systemic steroid , immunosuppressant therapy chemotherapeutic agent within 3 month study screening , expect receive agent study ( eg , corticosteroid , immunoglobulin , immune cytokinebased therapy ) . Evidence follow : 1 . Clinically significant ECG abnormality . 2 . Syncope , palpitation , unexplained dizziness . 3 . Liver disease ( include know Gilbert 's Disease ) clinical evidence liver injury hepatic synthetic dysfunction . 4 . Severe peptic ulcer disease , gastroesophageal reflux disease , gastric acid hypersecretory condition require prolong ( &gt; 6 month ) medical treatment . 5 . History medical surgical treatment permanently alter gastric condition ( eg , gastrectomy ) . 6 . Significant drug sensitivity drug allergy . 7 . Known hypersensitivity sulfa drug . 8 . Known hypersensitivity study drug , metabolites formulation excipients .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>RSV infection</keyword>
</DOC>